Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

Eli Lilly (LLY) weight loss therapy tirzepatide is on track to launch across England’s National Health Service ((NHS)) as ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...